Cost-effectiveness of screening for colorectal cancer with once-only flexible sigmoidoscopy and faecal occult blood test by Aas, Eline
 
 







screening for colorectal 
cancer with once-only 
flexible sigmoidoscopy 








Institute of Health Management 














of screening for colorectal cancer with  
once-only flexible sigmoidoscopy and faecal 





University of Oslo 



















* Eline Aas, Institute for Health Management and Health Economics and HERO, University of Oslo, Norway, 
eline.aas@medisin.uio.no 
 
I would like to thank Tor Iversen and John Dagsvik for helpful comments during the work of this paper and 
Statistics Norway for good collaboration during the data collection. Financal support from The Research Council 
of Norway through the Health Economics Research programme at the University of Oslo is acknowledged. 
NORCCAP (Norwegian Colorectal Cancer Prevention) and especially Geir Hoff are acknowledged. I will thank 
Per-Olov Johansson, Ivar S. Kristiansen, Jia Zhiyang, John Cairns and participants at the 6
th European 
conference in Health Economics ( Budapest July 2006), at the Workshop in Health Economics at Voksenåsen 
(Oslo, 2006) and the 27




                                  Health Economics Research Programme at the University of Oslo 
Financial support from The Research Council of Norway is acknowledged. 
ISSN 1501-9071 (print version.), ISSN 1890-1735 (online), ISBN 82-7756-190-3 





On the basis of a randomized controlled trial we estimate the cost per life-year gained for six 
different strategies for colorectal cancer screening. Individuals in the age group 50 to 64 years 
were randomly selected for either flexible sigmoidoscopy or a combination of flexible 
sigmoidoscopy and a faecal occult blood test. A comprehensive dataset was collected from 
the trial to estimate costs and gained life-years. There are some indications that screening for 
colorectal cancer can be cost-effective, but the results are not statistically significant after this 
short follow-up period.    
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1. Introduction 
  Colorectal cancer is one of the most frequent types of cancer in the Western World; in 
Norway it is the most prevalent. Screening or mass-examination of individuals without 
symptoms of cancer allows cancer to be diagnosed and treated at an asymptomatic stage. In 
addition, removal of polyps discovered during screening may prevent the development of 
future cancers. Since population screening is resource-demanding, a careful analysis of costs 
and health benefits needs to be undertaken to ensure that screening represents an efficient use 
of societal resources. In many European countries screening for colorectal cancer has already 
been introduced without proper evidence of its cost-effectiveness. 
The aim of this paper is to study whether screening for colorectal cancer is socially 
beneficial. If screening enables us to diagnose cancers in the asymptomatic stage, the cancers 
are less severe and the probability of surviving will increase. Removal of polyps is expected 
to prevent the development of future cancers. Prevention of future cancers will both reduce 
the probability of developing colorectal cancer and the probability of dying from colorectal 
cancer. These two effects will increase the health benefit. Further, the conclusion depends on 
consequences of screening on resource allocation.      
We develop a model to evaluate the cost-effectiveness of screening for colorectal 
cancer. The health benefit is measured as life-years gained and defined as the difference in 
life-expectancy for the screening group and the control group. Life expectancy depends on the 
probability of developing colorectal cancer, the probability of surviving from colorectal 
cancer and the probability of dying from causes other than colorectal cancer. These 
probabilities are estimated in the paper; screening is expected to reduce the two first 
probabilities. Total screening costs are analysed from a societal perspective and include costs 
such as direct program costs, treatment costs and production losses.  
From such a cost-effectiveness model we can derive information about the cost of 
screening per life-year gained; the marginal cost per life-year gained, by including an 
additional test; and the effect on cost of screening including avoided treatment costs and 
production gains.  
  The analysis is based on a comprehensive dataset collected from a randomized trial in 
Norway (NORCCAP – Norwegian Colorectal Cancer Prevention). This is a once-only 
screening with flexible sigmoidoscopy or flexible sigmoidoscopy in combination with a 
faecal occult blood test (FOBT). The Norwegian trial, together with screenings in the UK 
(Atkin et al. 2002), Italy (Segnan et al. 2002) and the US (Weissfeld et al. 2005), are the first    3 
randomized controlled trial of this type. The data set includes individual level data on trial 
costs, use of health care services, labour market participation, travel expenses, incidences of 
cancer with stage description, date of death, and socio-economic variables such as income, 
education, age, and gender. 
No screening is chosen as the comparator in this analysis. The study is undertaken 
from a societal perspective on the basis of ‘intention to treat’. ‘Intention to treat’ means that 
the comparison is made between those who were invited to screening versus those who were 
not, regardless of whether they had a screening examination or not. Because non-participants 
to screening are selective, we would introduce bias by comparing those who actually had 
screening with the control group. By including only participants, we cannot be certain 
whether the findings stem from the intervention or the fact that there is selection bias with 
regard to participation. Findings from sub-groups, such as participants and non-participants, 
along with findings for the whole intervention group will provide important information about 
how the effects are distributed among the sub-groups.  
  Results from the cost-effectiveness analysis show that the cost per life-year gained 
depends on which categories of costs are considered. When direct program costs are included 
screening with a combination of flexible sigmoidoscopy and FOBT for the age group 55 to 59 
years is the most cost-effective alternative, while when indirect program costs are included, a 
combination of flexible sigmoidoscopy and FOBT for the age group 60 to 64 years is 
preferable to other preventive health measures. Inclusion of treatment costs implies that 
screening with a combination of flexible sigmoidoscopy and FOBT for the age group 55 to 59 
years increases the cost per life-year gained, and thus become the most cost-effective 
screening strategy. The sensitivity analysis indicates that our findings are not robust.  
  The paper is structured as follows: Section 2 describes the randomized control trial. 
Section 3 presents the structure of the model and how the expected life-years and life-years 
gained are estimated. The estimation of the transition probabilities used in the model is 
presented in Section 4, where Section 4.1 and 4.2 present the estimation of the transitions 
from well to colorectal cancer or death and the transition from colorectal cancer to death, 
respectively. In Section 5 we present the four categories of screening costs used in the 
analysis: direct and indirect programme costs, and direct and indirect programme 
consequences. Section 6 presents life expectancy and cost-effectiveness results based on the 
four different screening cost alternatives, and Section 7 contains the uncertainty analyses. In 
Section 8 the underlying assumptions on which the results are based are discussed and 
compared with the literature. Section 9 offers some conclusions.    4 
2. Data 
NORCCAP (Norwegian colorectal cancer prevention, see Bretthauer et al. (2002)), 
was a randomized controlled trial in the period 1999-2001. NORCCAP was implemented in 
two counties: Telemark (165,855 inhabitants in 2003) and Oslo (517,401 inhabitants in 2003). 
Each year from 1999 to 2001, approximately 7,000 individuals were invited to participate in 
NORCCAP (3,500 from each county). In 1999 and 2000 individuals between 55 and 64 years 
were invited, while individuals between 50 and 54 years were invited in 2001. After one 
reminder letter, the overall participation rate reached 65 percent for the whole period. The 
probability of participation depends on individual characteristics such as income, travel 
expenses, expected benefit from screening, and the use of health care services (Aas, 2004 and 
2005). 
The NORCCAP trial was a once-only screening, and the screening methods used were 
flexible sigmoidoscopy and FOBTs
1. Half of the intervention/screening group was offered 
flexible sigmoidoscopy and the other half flexible sigmoidoscopy in combination with FOBT. 
Flexible sigmoidoscopy enables the physician to observe the inside of the large intestine from 
the rectum through the distal part of the colon (about 50 cm of the total colon), called the 
sigmoid colon. This procedure makes it possible to look for polyps
2, which are early signs of 
cancer. The FOBT is self-administered and requires stool samples on three consecutive days. 
The samples are smeared onto cards containing chemically impregnated paper and forwarded 
to the laboratory at the time of screening participation.  
Figure 1 describes the patient flow in NORCCAP. A participant fulfilling the 
inclusion criteria
3 has to empty his
4 bowels before undergoing the sigmoidoscopy. The 
sigmoidoscopy results can be either positive or negative, where a positive sigmoidoscopy is 
defined as having an adenoma < 10 mm and/or having a polyp ≥ 10 mm (it is more than 95 
percent certain that such a polyp is an adenoma). Adenomas are growths that are benign, but 
some are known to have the potential, over time, to transform into cancer. If the individual 
was invited to a combination of flexible sigmoidoscopy and a FOBT, the FOBT is analysed 
after the sigmoidoscopy. An individual with a positive sigmoidoscopy is referred for a work-
up colonoscopy, independent of the result of the FOBT, while the individual with a negative 
sigmoidoscopy is referred for a colonoscopy only if the FOBT is positive. Colonoscopy, like 
                                                 
1 The FOBT used here is a FlexSureOBT®, an immunochemical test for human blood. 
2 Polyps are outgrowths in the colon. The larger they are, the more likely they are to develop into cancer in the 
future. 
3 The exclusion criteria for NORCCAP included being treated for cancer and taking anticoagulants.  
4 Both males and females participated in the screening, but we refer to the individual as he.    5 
flexible sigmoidoscopy, enables the physician to observe the inside of the large intestine. 
Unlike flexible sigmoidoscopy, colonoscopy is an examination of the entire large intestine, 
both rectum and colon.  
    
 
   











Enema of the bowel 
All participants  Excluded 
 
Figure 1: NORCCAP and patient flow for individuals undergoing flexible sigmoidoscopy alone or in 
combination with FOBT.  
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  In NORCCAP the total screening group and control group were randomly drawn with 
regard to date of birth (see details in A1). The total screening group consists of all individuals 
invited to the screening, i.e., the participants, non-participants, the individuals excluded, and 
the individuals from whom the invitation letter was returned unopened. The criteria related to 
which cases to include in the sample are important in order to have comparable datasets. In 
the total screening group we have included all colorectal cancers and deaths from the start of 
the year in which they were invited. For individuals in the control group born in 1935 to 1945 
we have included all colorectal cancers and deaths from the start of either 1999 or 2000, 
depending on the year in which they were included in the control group (see A1 for details). 
For individuals born in 1946 to 1950 we have included all colorectal cancers and deaths from 
the start of 2001. As a consequence the control group was reduced from 79,808 to 79,191. 
The total screening group originally consisted of 20,780 but was reduced to 20,559 because 
86 individuals declined the data merger, 45 individual died and 131 developed colorectal 
cancer or died from it before the screening period. 
  In Table 1 the number of asymptomatic and symptomatic cancers, CRC deaths and 
deaths from causes other than CRC are reported according to age group and screening 
strategy. From the Table we see that there is a decline in colorectal cancer deaths for the two 
oldest age groups of 40 to 50 percent. The decline is largest for the groups offered a 
combination of flexible sigmoidoscopy and FOBT. 
 
Table 1: Proportions of asymptomatic and symptomatic diagnosed colorectal cancers and 
deaths, both colorectal cancer and causes other than colorectal cancer according to 
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causes) 
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  The dataset includes information about age, gender, date and cause of death, number 
of social security recipients, and labour market status from Statistics Norway. Data on 
incidences, time of diagnosis, and cancer stage of advancement at the time of diagnosis are 
obtained from the Cancer Registry of Norway; Baseline findings are from NORCCAP 
(Gondal et al. 2003). Information on both inpatient and outpatient services are from the 
National Patient Register and the National Insurance Administration. The data are from 1999 
to 2004.  
 
 
3. Structure of the model  
The expected benefits from screening for colorectal cancer using flexible 
sigmoidoscopy alone or in combination with FOBT are an increased probability of surviving 
cancer and a reduced number of future incident cancers. The first effect is a result of earlier 
detection of cancer since colorectal cancer often is diagnosed at a very late stage, which is 
negatively correlated with the survival probability. The second effect is a consequence of the 
removal of polyps from the colon, which otherwise could develop into cancer in the future. In 
this paper we apply the number of life-years gained as the effect measure.  
  Below we present a modelling framework for analysing the effect of screening on life 
expectancy. Several types of probabilities form the foundation of the model. The probabilities 
are presented in Table 2 where three types are of specific interest; the probability of 
developing colorectal cancer; the probability of dying from colorectal cancer, and; the 
probability of dying from causes other than colorectal cancer. If screening reduces the two 
first probabilities, life-expectancy will increase. The model consists of a number of mutually 
exclusive states, black and grey ovals, as displayed in Figure 2. The individual will always be 
in one and only one of the states at a given moment in time. During one cycle the individual 
can move from one state to another or remain in the same state. A set of transition 
probabilities describes the movement between the different states. Figure 2 presents the model 
applied to the estimation of costs and life-years gained for individuals invited to flexible 
sigmoidoscopy. In this model a cycle is one calendar year. The main states in the model are 
well, sick (defined as either having asymptomatic or symptomatic colorectal cancer), and 
dead. The white ovals represent intermediate states of screening procedures, which the patient 
may enter and leave during one cycle. Grey and black ovals are states in which the individuals 
can stay for at least one full cycle.  
    8 
Table 2: The probability applied in the model with definitions*. 
Probability Definition 
12() qX  The transition probability at age X in screening group g of being well and dying 
from causes other than colorectal cancer.  
13() qX   The transition probability at age X in screening group g of being well and 
diagnosed with a symptomatic colorectal cancer.  
32(; )
A qv X   The transition probability at age X of dying during treatment of an asymptomatic 
diagnosed colorectal cancer, where v refers to year after diagnosis. 
32(; )
S qv X   The transition probability at age X of dying during treatment of a symptomatic 
diagnosed colorectal cancer, where v refers to year after diagnosis. 
a   The probability of participating in screening group g. 
h   The probability of having a work-up colonoscopy in screening group g. 
c  The probability of being diagnosed with an asymptomatic colorectal cancer in 
screening group g. 
k   The probability in screening group, g of being recommended to take a follow-up 
colonoscopy t years after the screening. 
m   The probability in screening group g of having a valid FOBT. 
p   The probability in screening group g of being well at the start 
 * The estimates are reported in Appendix A2, A3 and A4. 
 
  An individual invited to screening has a probability a of participating in the screening 
and (1-a) of not participating (for various reasons). All non-participants are assumed to be 
well. When participants are examined by flexible sigmoidoscopy, a proportion of them, h, are 
referred further to a work-up colonoscopy, while (1-h) are defined as well. For individuals 
referred to a colonoscopy, the probability of having asymptomatic cancer is equal to c. As 
asymptomatic cancers are only diagnosed at the screening, the probability that an individual 
referred to colonoscopy is well is defined as (1 ) c − . Let  p  be the probability of being 
diagnosed with an asymptomatic cancer, then (1 ) p −  is the probability of being well at the 
start.  
Let t = 1, 2,…., 36, refer to the cycle (or year), superscripts S and A refer to whether 
the cancer are symptomatic and asymptomatic and the states be enumerated as follows: well is 
state one, death is state two and colorectal cancer is state three. The transition probability of 
being well at age  X  and diagnosed with symptomatic colorectal cancer is  13() qX  and the 
transition probability at age  X  of being well and dying of causes other than colorectal cancer 
is  12() qX . Let v = 1, 2, 3 and 4 refer to duration (years) from diagnosis, then the probabilities 
of dying during treatment of asymptomatic cancer is equal to  32(; )
A qv X  and the probability of 
dying during treatment of symptomatic cancer is equal to  ( ) 32 ;
S qv X . The details about the 
transition probabilities are presented in the next section.        9 
  A proportion of the individuals participating in the screening were recommended for 
follow-up colonoscopies after the screening (k ). Some individuals were recommended to do 
the follow-up colonoscopy five years after the screening, while others ten years after the 
screening, thus the probability depends on time. The proportions of recommended follow-up 
colonoscopy for each cycle is calculated based on data from the trial, see A4. These follow-
ups are included as intermediate states for an individual who is well. The probability that an 
individual at the follow-up colonoscopy will be diagnosed with colorectal cancer is defined as 
13() qX , and is assumed to be equal to the probability in the general population. If the 
individual does not have colorectal cancer at a follow-up colonoscopy, the individual is 
included in the state of well  13 [1 ( )] qX − .  
  Based on findings in Aas (2007) it is assumed that the total duration of treatments on 
average last for four years. Then, the probabilities of becoming well after four years of 
treatment for an asymptomatic diagnosed and a symptomatic diagnosed cancer are given by  
 









− ∏             (1)  









− ∏             (2) 
 
    All the probabilities used in the model are presented with definitions in Table 2. The 
estimates are reported in Appendix A2 and A4. The participation probability is equal to the 
probability of having a flexible sigmoidoscopy and is lower for the youngest age group. The 
number of work-up colonoscopies increases with age, which would be expected since the 
number of polyps in the colon is higher for the age groups 55 to 59 and 60 to 64 years. In the 
model, where a combination of flexible sigmoidoscopy and FOBT is evaluated we need to 
include the probability of having a valid test. A valid test is defined as a test in which it is 
feasible to examine one, two, or three of the stool samples. As the FOBT only is a supplement 
to flexible sigmoidoscopy, we have not included false positive estimates and have not 
modelled the effect of only FOBT on life expectancy or costs. 
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Figure 2: Screening by flexible sigmoidoscopy where black and grey ovals represent states in which 
patients remain for at least a full 1-year cycle. The white ovals represent intermediate states of 
screening procedures which patients may enter and leave during a cycle. The arrows represent 
transition between various states.    
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Based on the model introduced above, we can simulate life expectancy for the 
different screening strategies and the control group. Let the nine screening groups be 
represented by g = FS5054, FS5559, FS6064, COMB5054, COMB5559, COMB6064, C5054, 
C5559 and C6064, where g = 1, 2, …,9, respectively and  ( )
g Lt be the surviving probability at 
time t for screening group g. Since time of death is distributed over the cycle, we include half-
cycle correction, which reduce the health benefit (survival probability) to the half in the first 




2 0.5[ (1) ( )] ( )
T gg g g
t LEL L TL t
−
= =+ ∑ .        
                   
The probability of surviving t = 1 for screening group g at age  t X is given by:  
 
        
12 1 13 1
13 1 32 1
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Lp q X q X





                        (3)
   
The first line of (3) is the probability of remaining in the state well during cycle one, i.e. not 
dying from causes other than colorectal cancer and not being diagnosed with colorectal 
cancer. The second line is the probability of surviving the first year of treatment for 
symptomatic cancer, while the last line represents the probability of surviving the first year of 
treatment for asymptomatic cancer. The probability of surviving until the start of cycle three 
is given by    
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A X
        (4) 
 
Equation (4) contains of four parts: The first line in is the probability of remaining in the state 
well through cycle two, i.e. not dying from other causes than colorectal cancer or being 
diagnosed with symptomatic cancer in cycle two. Further, the second line is the probability of 
surviving until the third year of treatment for a symptomatic cancer diagnosed in cycle one. 
Line three is the probability of surviving until the second year of treatment of a symptomatic    12 
cancer diagnosed in cycle two. The last line is the probability of being diagnosed with an 
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where (5) is the probability of surviving until cycle 4. Let T = 36 and r be the discount rate, 
then life-years gained (LYG) for screening group 1 is given by  
 
    { }
1( 1 ) 7 (1 )
tg LYG r LE LE
−− =+ −                (6) 
 
 
4. Transition probabilities   
  
4.1 Transition from well to colorectal cancer or to death from causes other than colorectal 
cancer 
  In this Section we estimate the transitions from well to colorectal cancer ( 13 q ) and 
from well to death ( 12 q) . We have data on colorectal cancer diagnosis and deaths from 1999 
to 2004 for which number of years of observation ranges from a maximum of six (for 
individuals invited in 1999) to a minimum of four (for individuals invited in 2001). The 
variation in age ranges from 50 to 69 years.  
Because groups were limited we have simplified the estimation by assuming that 
observations for an individual are independent over time. This implies that an individual 
surviving six years is counted as six different individuals all being well, while an individual 
surviving until dying after four years is counted as three well individuals and one dying. If 
there are unobserved individual-specific factors that are correlated over time, the transition 
over years will not be independent and accordingly the estimates of the model parameters will 
be biased. This potential bias is however not expected to have an impact on the comparison 
between the screening group and the control group because there is no reason to believe that 
the correlation over time will be affected of screening.      13 
Let j refer to the state to which the individual can transfer, j = 2 and 3. The transitions 
are independent of time and duration, but change with age, X, and intervention group, 
g=FS5054, FS5559, FS6064, COMB5054, COMB5559, COMB6064, C5054, C5559 and 
C6064. The probability for individual i to transform from well to CRC or death is assumed to 
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where i = 1, 2, …. N,  j=2 and 3,  02 03 12 13 ,, a n d   β ββ β  are parameters to be estimated by the 




   LogL  = 
3
11 12 log ( )
N
ij ij ij Yq X
== ∑∑                          (8) 
 
  The parameters in (8) are estimated by the maximum likelihood method
6. The results 
from the estimation are reported in Table 3 and presented according to age groups. The 
transition from well to both death and colorectal cancer increases with age.  
For all age groups in Table 3, the control group for a specific age group is the 
reference group and the parameter estimates are only reported for the screening strategies 
within the relevant age group. For the age group 60 to 64 years, there are no significant 
differences between the control and the two intervention groups with regard to the effect on 
death and colorectal cancer. For the age group 55 to 59 years a combination of flexible 
sigmoidoscopy and FOBT has a significant negative effect on death, while only flexible 
sigmoidoscopy has a significant negative effect on the probability of developing colorectal 
cancer. In the age group 50 to 54 years the only significant effect is the negative effect on the 




                                                 
5 For further details on multinomial logit, see Green (2002) 
6 Estimated with STATA release 8.    14 
Table 3: Parameters estimates of the multinomial logit model (SD in parenthesis). No. of 







60 to 64 years 
 
55 to 59 years 
 
50 to 54 years 
Death 
(j=2) 
     
  Age  0.00033 (0.00003)***  0.00033 (0.00003)***  0.00033 (0.00003)*** 
  Screening  group       
              C5054  -  -  Ref. 
              FS5054              -  -  0.00003(0.0005) 
              COMB5054  -  -  -0.00052(0.0005) 
              C5559  -  Ref.      - 
              FS5559  -  -0.00032 (0.0003)  - 
              COMB5559  -  -0.0007 (0.0003)**  - 
              C6064  Ref.  -  - 
              FS6064  -0.00013 (0.00036)  -  - 




     
  Age  0.00004 (0.00001)***  0.00004 (0.00001)***  0.00004 (0.00001)*** 
  Screening  group       
              C5054  -  -  Ref. 
              FS5054              -  -  -0.00036 (0.0001)*** 
              COMB5054  -  -  0.00001(0.00021) 
              C5559  -  Ref.  - 
              FS5559  -  -0.00026 (0.0001)***  - 
              COMB5559  -  -0.00015(0.0001)  - 
              C6064  Ref.  -  - 
              FS6064  -0.00009 (0.00011)  -  - 
              COMB6064  -0.00002 (0.00012)  -  - 
*** Significant at 1 percent level, ** Significant at 5 percent level, * Significant at 10 percent level 
 
 
  The estimated coefficients are used to predict the transition probabilities for the age 
groups 50 to 67. The predicted probabilities are then used to simulate the surviving 
probabilities for the first six cycles. However, as the variation in age is limited, we used 
information from the Cancer Registry of Norway and Statistics Norway to predict the 
transitions from cycle 7. From cycle 7, it is assumed that for a given age the transitions are 
equal for the screening groups and the control group. Hence, due to insufficient information, 
we do not include the effect of screening on the probability of developing colorectal cancer in 
the future. The transitions are reported in Appendix, A3. 
 
4.2 Transition from colorectal cancer to death 
  In this Section we estimate the transitions from colorectal cancer to death  32(; )
A qv X  
and  32(; )
S qv X the first four years after diagnosis. We have data on colorectal cancer diagnosis 
and deaths from 1999 to 2004 for which number of years of observation ranges from a    15 
maximum of six (for individuals invited in 1999) to a minimum of four (for individuals 
invited in 2001).  The variation in age ranges from 50 to 69 years. In Aas (2007) it is shown 
that the transition from colorectal cancer to death is independent of duration within the age 
group 50 to 69, thus the probability of dying during treatment of asymptomatic and 
symptomatic cancer are  32 32 ()  a n d   ()
AS qX qX , respectively. From Aas (2007) we know that 
treatment costs for colorectal cancer are approximately zero five years after diagnosis. Based 
on this, we assume that all individuals, except those dying during treatment, are treated for 
colorectal cancer within four years of diagnosis. The transitions are assumed to depend on age 
at the time of diagnosis, X, and whether the cancer is diagnosed due to symptoms or not
7. The 
transition probability for individual i  diagnosed with an asymptomatic and symptomatic 
cancer to die one out of four years of treatment of colorectal cancer is then estimated by the 
logit models: 
 












⎛⎞ =− ⎜⎟ + ⎝⎠
             (9) 












⎛⎞ =− ⎜⎟ + ⎝⎠
                        (10)
   
   To estimate the probability in (9) we use data for 41 asymptomatic cancers out of 
which two died within four years of treatment. To estimate (10) we use 471 symptomatic 
cancers out of which 159 died during four years of treatment. We use the maximum 
likelihood method
8. The results are presented in Table 4. We see that age do not have any 
significant effect on the probability of dying, thus the probability of dying during four years 
of treatment is independent of both age and duration. The probability of dying is then constant 
over the four years. For asymptomatic diagnosed cancer  32( ) 0.012
A qX =  and for symptomatic 
cancer  32()0 . 0 9 7
S qX = . The transitions are reported in A3. The predicted probabilities are 
used to simulate the conditional probability of being well at the start of cycle t and surviving 
until cycle t+1 for the six first cycles.     
 
 
                                                 
7 The transition is in Aas (2007) shown to depend on variables like education and Dukes stages, but these factors 
are not included here since they are not needed in the estimation of life-expectancy.   
8 Estimated with STATA release 8.    16 
Table 4: Parameter estimates from the logit model (SD in parenthesis). No of observation are  
513 out of which 41 is asymptomatic.   
Screening group  Variable   Coefficients 
Asymptomatic diagnosed cancer    
  Age  - 0.0058 (0.009) 
    
Symptomatic diagnosed cancer    
  Age  - 0.0033 (0.005) 
*** significant at a 1 per cent level, ** significant at a 5 per cent level, * significant at a 10 per cent level 
 
  Technically, the model can predict transition for all cycles, but as we know that 
increasing age is expected to reduce survival and survival is also expected to depend on the 
duration (Cancer Registry of Norway, 2003), we do not use the result in Table 4 to predict 
beyond cycle six. From cycle 7 we supplement with data from the Cancer Registry of Norway 
and Statistics Norway (Statistics Norway, 2004). From cycle seven, the deaths during 
treatment of symptomatic colorectal cancer include only colorectal cancer as cause of death. 
From the Cancer Registry of Norway we know that the probability of dying depends on time 
from diagnosis, about 58 percent of the deaths occur within the first year and 20, 13, and 9 
percent during the second, third, and fourth years, respectively (the transitions used are 
reported in A3). 
 
 
5. Screening costs 
  We divided the costs into four categories, which allow us to analyse how inclusion of 
different cost estimates affect the cost per life-year gained. It also facilitates comparison with 
relevant literature because previous analyses on cost-effectiveness of colorectal cancer 
screening include various cost estimates.   
  The first category encompasses the direct program costs and includes the opportunity 
cost of all resources used to carry out the screening (Table 5). The cost of invitations to 
screening and reminder letters is a rough estimate that includes stamps, envelopes, and letters. 
Reimbursement from the National Insurance Administration is used to estimate the cost of 
diagnostic sigmoidoscopy and therapeutic colonoscopy. On the basis of a Norwegian study 
(Samdata somatikk, 2004) we have adjusted all the fees from the National Insurance 
Administration by a factor of 1.5 to reflect the true cost. The price of Laxabon® for bowel 
cleansing before a colonoscopy is the market price the individual has to pay at the pharmacy.  
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Table 5: Direct program costs, unit price, and source of information (prices from 2003)  
Screening costs  Unit cost (Euro)  Source 
Invitation letter             2  Expert opinion 
Reminder             2  Expert opinion 
Diagnostic sigmoidoscopy         180  The National Insurance Administration 
Therapeutic colonoscopy (inclusive 
polypectomy and biopsy) 
       225  The National Insurance Administration 
Laxabon® - bowel cleansing          8.75  Market price 
FOBT test in the letter           3  Expert opinion 
FOBT examination           5  Expert opinion 
 
  The indirect program cost is the second cost category and includes the individual’s 
travel expenses to the screening and, if required, to the colonoscopy (if he had a high or low 
risk adenoma). From Aas (2004, 2005) we know that average travel expenses for those 
participating were 9 Euro. Furthermore, the indirect program costs also contain production 
losses resulting from travel time to the screening examination and/or to the colonoscopy and 
the time used on the sigmoidoscopy and/or the colonoscopy examination. On average, the 
time travelling to the screening centre for a flexible sigmoidoscopy screening examination or 
colonoscopy is 1 hour and 15 minutes, see Aas (2005). Preparation at the centre and 
sigmoidoscopy takes about 45 minutes so the total screening time (travelling and 
sigmoidoscopy) is two hours. Since the colonoscopy requires bowel preparation before the 
examination
9 and the examination itself is more extensive than a flexible sigmoidoscopy, it is 
assumed that total colonoscopy time (travelling and colonoscopy) is one day. Because there is 
almost no unemployment in Norway, we use the human capital approach to estimate the 
opportunity cost of the production loss. The production losses depend on the age of the 
individual because the proportion working declines with age. From Aas (2004, 2005) we 
know that the proportion working in the age groups 50 to 54 years, 55 to 59 years, and 60 to 
64 years is 0.82, 0.81 and 0.62, respectively. Production loss per day is calculated on the basis 
of gross income reported for individuals responding to the survey used in Aas (2004, 2005).  
From Table 6 we see that the production loss declines with age, which can be 
explained by an increasing proportion working part time in the older age groups. We have 
assumed the opportunity cost for individuals not working is equal to zero.      
 
                                                 
9 The bowel cleansing has to start at 4 pm on the day before the colonoscopy.     18 
Table 6: Indirect program costs, unit price and source of information (2003)  
Screening costs  Cost (Euro)  Source 
Travel expenses  9  Aas (2004, 2005) 
Production loss per day    
                                                        50 to 54  311  Aas (2004, 2005) 
                                                        55 to 59  306  Aas (2004, 2005) 
                                                        60 to 64  288  Aas (2004, 2005) 
        
 
  The third category is direct program consequences. There are two direct program 
consequences with regard to treatment cost of colorectal cancer. The first effect is reduced 
future treatment cost resulting from reduction in future incidence of colorectal cancer and the 
second effect reflects the fact that screening allows diagnosis of asymptomatic cancers, which 
are less expensive to treat
10. In Table 7 treatment cost is presented for symptomatic and 
asymptomatic cancers and includes surgery, chemotherapy, and follow-up colonoscopies 
(radiotherapy is not included). The treatment follows certain standard procedures (Norwegian 
Gastrointestinal Cancer Group, 1999), but there is room for individual variation. The 
treatment costs are estimated on the basis of information about inpatient stays and outpatient 
consultations from the National Patient Register and the National Insurance Administration. 
We use hospital reimbursement as the basis for estimating treatment costs. The hospitals have 
“activity-based financing” based on diagnosis-related groups (DRG). The DRG system 
classifies hospital services into groups that are medically related and homogeneous with 
regard to use of resources. DRGs describe a hospital's case-mix. In Norway there are 
approximately 500 different DRGs. Each DRG
11 is given a weight that reflects the treatment 
cost. For outpatient services the fee for service only partly covers the true cost. On the basis 
of a Norwegian study (Samdata somatikk, 2004) we have adjusted all the reimbursements 
from the National Insurance Administration by a factor of 1.5 so that they reflect the true cost. 
We use the DRG weights for 2003 for all years since there have been no major changes in the 
treatment for colorectal cancer.  
  To estimate the treatment cost we use all registered care directly related to the 
treatment of colorectal cancer from our database
12. The data stems from the National Patient 
                                                 
10 Details will be published a forthcoming paper by Aas, 2007. The effect of screening on treatment cost – the 
case of colorectal cancer. 
11 The unit price of a DRG is equal to Euro 3,706 in 2003. 
12 For details on the estimation of the estimation of treatment costs, see Aas (2007).    19 
Register with the appropriate fees, DRGs, and DRG weights. Treatment costs are estimated 
for asymptomatic cancers and symptomatic cancers. The estimation is done in several steps: 
first, calculating treatment cost per registration; second, estimating total treatment costs per 
month for the stage by adding the treatment cost per registration for each month for all 
individuals in the stage; third, estimating the average treatment costs per month for the stage 
by dividing total treatment cost per month for that stage by the sum of individuals diagnosed 
with cancer at that stage and  alive in that specific month; fourth, adjusting the average 
treatment cost per month for estimated survival per month according to Dukes stage; and 
finally, adding together the average treatment cost per month over the whole period to arrive 
at the expected colorectal cancer treatment cost for either a Dukes stage or a participation 
group.  
  On average, the treatment period lasts for four years after diagnosis, see Aas (2007). In 
the model we assume that recurrences are indirectly captured in the treatment cost. The 
treatment of symptomatic cancers costs about 9,000 Euro more than asymptomatic cancers. 
 
 
Table 7: Treatment cost for colorectal cancer according to date of diagnosis and year from 
diagnosis  
Category First  Second  Third  Fourth  Total 
Symptomatic cancers  18,880  4,718 2,734 1,908  28,240 
Asymptomatic cancers  16,416 2,058  493  196  19,163 
 
  In addition to treatment costs, the direct consequences also include costs related to 
future recommended follow-up colonoscopies. The recommendation for the majority of 
colorectal cancer patients is to have a five-year follow-up colonoscopy, but for some patients 
an earlier follow-up plus an additional colonoscopy up to ten years after screening are 
recommended. The last follow-up is in cycle 11. We use the costs per colonoscopy in Table 6. 
Probabilities are reported in Appendix A4. 
Finally, the fourth category of costs is the indirect program consequences. This 
includes travel expenses and production loss resulting from future recommended 
colonoscopies and production gain due to early detection or reduced severity. If the screening 
prevents future incidences, this could also result in production gains. We use the estimates of 
travel expenses and production loss reported in Table 6 and the probabilities in Appendix A4 
to calculate production loss for future recommended colonoscopies.  
 
    20 
Table 8: Descriptive statistics on the number of days of sick leave according to age group and 
time of diagnosis (asymptomatic and symptomatic)   
Age group  Diagnosis  Mean  N  Std. dev 








   Asymptomatic 199.83  6  199.6 








   Asymptomatic 281.92  13  119.3 








   Asymptomatic 255.67  9  114.8 








  Asymptomatic 255.89  28  136.5 
 
 
To estimate production gains we test whether or not there are differences in the 
number of days of sick leave after a cancer diagnosis between asymptomatic diagnosed 
cancers and symptomatic cancers. We use information from Statistics Norway about a 
number of social security recipients, labour market status, and number of days of sick leave to 
estimate the production gain. In Table 8 the number of days of sick leave is reported for 
individuals working at the time of diagnosis according to age group and whether the cancer 
was diagnosed at an asymptomatic or symptomatic stage. While there is almost no difference 
in number of days of sick leave according to symptomatic or asymptomatic stage for the two 
oldest age groups, there is a difference for individuals in the age group 50 to 54 years. This 
indicates that early diagnosis results in some production gains for the youngest age group. 
However, because the standard deviation is large, the difference is not statistically significant 
and we have therefore not included production gains in the model.   
  Let 
g C  be total screening costs for screening group g over all cycles. The incremental 
screening costs ( C Δ ) for screening group 1 is then given by 
 
   
1( 1 ) 1 7 (1 )
t Cr C C





  In this analysis we simulate cost per life-year gained for six alternative strategies
13. 
There are three age groups (50-54, 55-59, 60-64 years) and two screening interventions, 
                                                 
13 We use TreeAge Pro 2005 in the estimation of the model.    21 
flexible sigmoidoscopy alone or in a combination with FOBT. We discount both costs and 
effects and apply a discount rate equal to four percent, which is according to Norwegian 
guidelines from The Norwegian Ministry of Finance (2005). Based on equation (6) and (11), 
cost per life-year gained for (










=                                (12)
    
In Table 9 the estimated life expectancy (
g LE ) in years is reported for all six strategies and 
the control groups based on the principle of ‘intention to treat’. The expected life-years gained 
(LYG) are also reported. The largest gain in life expectancy is in the age group 60 to 64 years, 
for an individual invited to both flexible sigmoidoscopy and FOBT; the age group 55 to 59 
years invited to a combination of flexible sigmoidoscopy and FOBT has the second largest 
gain. From the findings in Tables 1 and 3, we would expect that largest increase in life-years 
would be for individuals in the age groups 55 to 59 years or 60 to 64 years. The probability of 
dying during treatment of an asymptomatic diagnosed cancer is 5 percent each year 
(compared with 11.5 percent for a symptomatic diagnosed cancer). There is a large difference 
in life-years gained between screening with only flexible sigmoidoscopy and the combination 
of flexible sigmoidoscopy and FOBT. The results are driven by the difference in the 
probability of dying from causes other than colorectal cancer. As the samples in the different 
screening groups are small with regard to death, the difference can occur by chance. If, 
however, there is a positive relationship between the probability of dying during treatment of 
colorectal cancer and deaths from causes other than colorectal cancer (for instance from 
pneumonia), early detection may also reduce the probability of dying from other causes 
during the first years after the screening.           
  Initially, 2,632 individuals in the age group 60 to 64 years were invited to a 
combination of flexible sigmoidoscopy and FOBT. Given the increase in life expectancy 
shown in Table 9, a total number of 237 life-years are gained
14. From Statistics Norway we 
find average life expectancy for an individual 62 years of age to be approximately 20 years; 
thus, approximately 12 individuals could live until the age 82
15. As the number of life-years 
gained is zero for the age group 50 to 54 with only flexible sigmoidoscopy, reporting cost-
effectiveness is not meaningful.    
                                                 
14 2,632*0.09 = 237 life-years gained. 
15 237/20 = 12    22 
  Table 9 also presents the results from the cost-effectiveness analyses presented. There 
are four different estimations representing different cost categories. In three out of four 
alternatives, screening the age group 55 to 59 years with a combination of flexible 
sigmoidoscopy and FOBT is the most cost-effective alternative.  
  When only direct program costs are considered, the cost per life-year gained is Euro 
1,633
16. The second most cost-effective alternative is screening the age group 60 to 64 years 
with a combination of the two tests, closely followed by the age group 55 to 59 years 
examined only with flexible sigmoidoscopy. Inclusion of indirect program costs increases the 
cost per life-year gained to Euro 2,156, but it also changes the most cost-effective alternative 
to the age groups 60 to 64 years with both flexible sigmoidoscopy and FOBT. The change in 
the most cost-effective alternative can be explained by a higher proportion working in the age 
group 55 to 59 years. The difference in cost-effectiveness between the second and third most 
cost-effective alternatives increases since a larger proportion is working in the younger age 
groups.    
  Taking direct program consequences into consideration increases the costs per life-
year gained for all screening strategies, and changes the ranking of the most cost-effective 
alternative. Inclusion of direct program consequences implies a reduction in cost per life-year 
gained for both screening strategies in the age group 55 to 59, while for the other age groups 
it implies an increase in cost per life-year gained. This changes the ranking of the strategies as 
the inclusion of treatment costs implies that the most cost-effective alternative changes to the 
age group 55 to 59 years with a combination of the two tests. The age group 60 to 64 years 
with a combination of the two tests has the second lowest cost per life-year gained. The 
increase in cost per life-year gained in the age group 55 to 59 years is smaller than the 
increase in cost per life-year gained in the age group 60 to 64 years, which can be explained 
by different proportions of asymptomatic diagnosed cancers. In the age group 60 to 64 years, 
the asymptomatic cancers constitute of a smaller proportion of the total number of diagnosed 
cancers than in the younger age groups (see Table 1). Direct program consequences include 
costs resulting from future follow-up colonoscopy. These costs will, for all alternatives, 





                                                 
16 147/0.09=1,633    23 
Table 9: Life-years, screening costs and costs per life-year gained according to screening 
strategy and groups of screening costs (monetary units in Euro)  
Strategy        Effect       Cost alt. 1*       Cost alt. 2**      Cost alt. 3***    Cost alt. 4**** 
















FS5054  16.74    0.00  137 -  189 -  1,025 -  1,034  - 
















FS5559  15.41  0.04  151 3,775  208 5,200 1,155  5,175 1,169  5,525 






  - 
 
0 
   
0 
   
1,040 
   
1,040 
 
FS6064  13.84  0.01  153 15,300  194 19,400 1,271  23,100 1,285  24,500 
COMB6064  13.92 0.09  151  1,678  194  2,156  1,259 2,433  1,271  2,567 
* Cost alternative 1 includes the direct program costs 
** Cost alternative 2 includes the direct and indirect program costs 
*** Cost alternative 3 includes the direct and indirect program costs and direct program consequences 
**** Cost alternative 4 includes the direct and indirect program costs and direct and indirect program consequences 
 
A reduction in future incidences implies a further reduction in the cost per life-year 
gained. Access to additional data can help determine whether or not the screening method will 
prevent future incidence of cancer.  
The last cost alternative consists of the indirect programme costs. These costs are 
related to travel expenses, the use of Laxabon® for bowel cleansing, and production loss due 
to time used on future recommended follow-up colonoscopies. The age group 55 to 59 years 
screened with a combination of flexible sigmoidoscopy and FOBT is also the most cost-
effective alternative in this cost alternative. 
  In Table 10 the incremental cost-effectiveness ratio (ICER) based on cost alternative 4 
in Table 9 is reported. The ICER is defined as the incremental cost per incremental effect. 
Because screening is a once-only event, all screening strategies are mutually exclusive and 
must be compared. The screening strategies are reported in ascending order according to cost, 
where costs reported are the difference in cost between a screening group and the control 
group. The incremental cost is the increase in cost between screening strategies
17. Life-years 
gained (LYG) (also reported in Table 9) and incremental LYG
18 are reported in columns four 
and five, respectively. The ICER is reported in column six
19 and we see that the ICER for the 
age group 55 to 59 years with a combination of flexible sigmoidoscopy and FOBT is Euro 
160. All the other screening strategies are dominated because the incremental cost is positive 
and the incremental effect is ether zero or negative.  
 
                                                 
17 The incremental cost for COMB5559 is equal to 229 – 221 = 8   
18 The incremental effect for COMB5559 is equal to 0.09 – 0.04 = 0.05 
19 The incremental effect for COMB5559 is equal to 8/0.05 = 160    24 
Table 10: The incremental cost-effectiveness ratio according to screening strategy. Monetary 
units in Euro. 
Strategy  ∆C* Incremental 
cost 
LYG Incremental  LYG  ICER 
FS5559  221   0.04    
COMB5559  229 8  0.09  0.05  160 
COMB6064  231 2  0.09  0.00  (Dominated) 
FS6064  240 9  0.01  -0.08  (Dominated) 
COMB5054  289 49  0.02  -0.07  (Dominated) 
FS5054  310 21  0.00  -0.09  (Dominated) 
*Cost alternative 4 includes the direct and indirect program costs and direct and indirect program consequences 
 
 
7. Sensitivity analysis 
  The estimation of life-years gained and costs in the model consists of several factors. 
Some of these factors are uncertain. In this section we want to test whether the inclusion of 
uncertainty changes the findings from Section 6, and give an indication of which type of 
uncertainty tends to most affect the findings.  
  Two types of sensitivity analysis are included in this paper. First, we use deterministic 
sensitivity analysis to see how one factor at a time influences cost-effectiveness. Second, we 
include a probabilistic sensitivity analysis (PSA), which is a parametric method, as we make 
assumptions about the distribution. Both the U.S. panel on cost-effectiveness analysis (Gold 
et al. (1996)) and the National Institute of Clinical Excellence (NICE) in the UK (2006) have 
suggested using PSA to deal with uncertainty in cost-effectiveness models because a well-
conducted PSA will provide a more realistic representation of variations in the model results. 
All uncertainty in the parameters is included simultaneously in a PSA. The uncertainty in a 
specific parameter is represented by a distribution.  
  In Table 11 the results from the deterministic sensitivity analysis are presented. All of 
the alternatives are based on the fourth cost alternative (all costs included) from Table 9 in 
Section 6. In alternative 1 we have increased the value in the fee-for-service for 
sigmoidoscopy and colonoscopy to account for uncertainty in the estimate of the true 
marginal cost. Alternative 1 includes the cost per life-year gained by assuming a doubling of 
the fee-for-service (Samdata somatikk, 2004). The cost per life-year gained is increased for all 
strategies, but the ranking remains unchanged. 
  The simulation of treatment costs is based on stage of advancement. Because 
treatment costs increase with stage of advancement, the treatment costs for asymptomatic    25 
cancers is lower than for symptomatic cancers
20. Stage of advancement is measured in groups 
and not on a continuous scale, thus there will be variations in costs within each group and our 
predictions will be the expected costs of recommended treatment. In addition, even though 
there are guidelines for the treatment of colorectal cancer, health personnel at one hospital or 
within one hospital may have different views on the amount or type of treatment, like 
chemotherapy, necessary for a specific patient. The cost predictions are based on fees and 
DRGs. These are average predictions and in some situations do not reflect the true treatment 
cost for a particular patient. For example, the same type of treatment according to the DRG 
for two individuals of different ages may call for a different use of resources. If the older 
individual recovers more slowly, he will need a longer stay in hospital than the younger 
individual, a difference that is not necessarily reflected in the DRG. Complications due to 
treatment of other diseases concurrent to the treatment for colorectal cancer may also result in 
variations in treatment costs. Alternative 2 in Table 10 shows the cost-effectiveness based on 
the assumption that the treatment costs for asymptomatic cancers is equal to the treatment 
costs for symptomatic cancers. This assumption increases the cost per life-year gained for all 
screening strategies, for the most cost-effective alternative by about Euro 5,500.  
 
 
Table 11: The effect on costs per life-year gained of changing the value of some of the factors 
used in the model according to screening strategy (monetary units in Euro).  
Strategy  Alt 1  Alt 2  Alt 3  Alt 4 
      ∆C      CE     ∆C     CE     ∆C      CE       LE    CE 
C5054  724  724  724   28.79   
FS5054  1,078 - 1,773 - 1,031 - 28.78 - 
COMB5054  1,051 16,350  1,749 51,250 1,010 14,300  28.80 31,000
C5559  948  948  948   25.23 
FS5559  1,218  6,750 1,862  22,850 1,167  5,475 25.29      3,683
COMB5559  1,223  3,056  1,714  8,511 1,175  2,522  25.38    1,527
C6064  1,040  1,040  1,040  21.41 
FS6064  1,335 29,500  1,874 83,400 1,291 25,100  21.43 12,250
COMB6064  1,331 3,233  1,866 9,178 1,277 2,633  21.60    1,215
Alt 1:  The cost of sigmoidoscopy and colonoscopy is 240 Euro and 300 Euro, respectively.  
Alt 2:  Equal treatment costs for asymptomatic and symptomatic diagnosed cancers 
Alt 3:  Production loss per individual estimated to be equal to 225 Euro for all three age groups 
Alt 4:  No discounting of health benefits 
 
  The third alternative includes a different prediction of the production loss resulting 
from time required for the screening and the colonoscopy. The estimates used in the 
simulation of total screening costs are based on Aas (2004, 2005), however, not all 
participants answered the questionnaire so the estimates could be biased. We therefore include 
                                                 
20 For details, see Aas (2007).    26 
an estimate from another Norwegian study (Hem, 2000) where the average wage per day is 
equal to Euro 225. From Table 11 we see that this change implies a very small to change the 
cost-effectiveness.  
  Although the recommended procedure is to discount both costs and health effects at 
the same rate (NICE, 2006 and Drummond et al., 2005), there are arguments for not 
discounting health benefits at all or for doing so using a lower discount rate than for costs (see 
Drummond et al., 2005). We have included an alternative where the health benefits are not 
discounted in order to see the magnitude of the effect of discounting on the health benefits. 
Comparing the findings in Table 11 with the life-expectancy in Table 9, we see that life-
expectancy for most alternatives will increase by eight to twelve life years, and that all cost-
effectiveness ratios decline. The ranking is unchanged.    
  In Section 4 we concluded that estimates of the differences in number of days of sick 
leave are too uncertain to be included in the model. Still, there were some indications in Table 
8 that there were potential production gains in the age group 50 to 54 years. We have 
therefore tried to estimate the difference in number of days of sick leave that would be needed 
to change the ranking of the cost-effectiveness in Table 9. In order for the age group 50 to 54 
years with both flexible sigmoidoscopy and FOBT to be ranked as the most cost-effective 
strategy, the difference in number of days of sick leave would have to be 505 days.  
  From the deterministic sensitivity analysis we see that there are changes in the cost-
effectiveness levels and the rankings, but the changes are relatively small. Thus, any decisive 
change in the cost-effectiveness must stem from uncertainty in the estimates of the transition 
probabilities.  
  In the probabilistic sensitivity analysis we include the uncertainty in the cost of 
sigmoidoscopy and colonoscopy, variation in the treatment costs, together with uncertainty in 
the transition probabilities. The cost of sigmoidoscopy and colonoscopy are assumed to be 
uniformly distributed with variation from 1.5 to 2 times higher than the fee for service 
reimbursement from the National Insurance Administration (Samdata somatikk, 2004).     
  With regard to the distribution of the treatment costs, we use findings from the 
bootstrap in Aas (2007). Bootstrapping is a method for assigning measures of accuracy to 
statistical estimates, in the present case the treatment cost estimates. We use bootstrapping to 
estimate the standard error (see Efron and Thibshirani 1993) of the treatment cost shown in 
Table 7. The bootstrap standard error is estimated by using the original samples. A bootstrap 
sample (equal to n) of treatment cost in year 1 is obtained by random sampling n times, with 
replacement, from the original sample, which means that some of the observations will be    27 
sampled once, others several times and some not at all. The method generates a large number 
of bootstrap samples, each of size n. We reapply the estimator (for instance the treatment cost 
in year 1) from each bootstrap sample and calculate the standard deviation. Mean and 95 
percent confidence intervals are presented in Table 12 according to asymptomatic or 
symptomatic diagnosed cancer and year from diagnosis. The confidence interval is 
overlapping for the two first years. Because colorectal cancer treatment cost only has positive 
values, we use gamma distributions to represent uncertainty (Spiegelhalter et al., 2004). To 
estimate the coefficients in the gamma distribution, we use calculated mean and variance from 
the bootstrap. The assumptions used in the PSA are presented in Appendix A5.   
 
Table 12: Mean and 95 percent confidence intervals for mean treatment costs for 
asymptomatic and symptomatic diagnosed cancers according to year from  
diagnosis. Numbers in Euro. 
Year Asymptomatic  Symptomatic 
  Mean  95 percent CI  Mean  95 percent CI 
1  16,416 (13,638  –  20,127) 18,880 (17,614  –  20,461) 
2    2,058  (923 – 4,161)    4,718  (3,509 – 6,385) 
3       493  (238 – 1,091)    2,734  (1,608 – 4,692) 
4       196  (91 – 463)    1,908    (582 – 6,837) 
 
  
  We include uncertainty in the transition probabilities by letting the transition 
probabilities for each stage vary by ten percent, and let the variation be represented by a 
uniform distribution. For each stage, the estimated coefficients represent by a minimum and a 
maximum value. We then use a Monte Carlo simulation to estimate the uncertainty in the 
parameters by selecting values from the distributions. Monte Carlo simulation in TreeAge 
recalculates the model repeatedly as a form of (deterministic) sensitivity analysis. We assume 
that the parameters are independent. The results from the PSA analysis are presented in Table 
13.  
  The first column in Table 13 presents the mean life-years for all groups. The second 
column reports the 95 percent confidential interval for life-years for the six screening groups. 
All confidence intervals are overlapping with the mean life-years for the corresponding 
control group. For instance, the mean life-years in the age group 55 to 59 years are 15.36 for 
the control group. The 95 percent confidential interval for the mean life-years for the age 
group 55 to 59 years with only flexible sigmoidoscopy and the combination of the two tests 
are 15.14 to 15.70 and 15.17 to 15.74, respectively. The third column presents the mean costs 
from the PSA analysis, while the fourth column reports the 95 percent confidence interval for    28 
the screening costs for the six screening groups. For all screening strategies, the costs are 
significantly higher than the control group. The results from the PSA imply that the results are 
statistically non-significant for all screening groups, both with respect to costs and life-
expectancy. 
 
Table 13: Mean and 95 percent confidential interval from PSA of screening cost and life-year 
according to screening strategy. Numbers in Euro. 
Strategy Mean 
life-years 











FS5054  16.74  (16.52 – 16.96)  1,032  (940 – 1,132) 








                    
FS5559  15.42  (15.14 – 15.70)  1,167  (1,070 – 1,271) 









FS6064  13.84  (13.53 – 14.19)  1,284  (1,175 – 1,402) 
COMB6064  13.92  (13.61 – 14.26)  1,269  (1,147 – 1,404) 
 
 
8. Discussion   
As pointed out in the introduction, NORCCAP is one of four RCTs that evaluate once-
only flexible sigmoidoscopy, but several cohort studies have also been conducted. Frazier et 
al. (2000) find that the cost per life-year gained for a once-only flexible sigmoidoscopy at the 
age of 55 is $ 1,200. Leshno et al. (2003) find that the cost per life-year gained is about $ 
1,237 for a combination of annual FOBT and flexible sigmoidoscopy every fifth year when 
only those participants with high-risk polyps are referred to a follow-up colonoscopy. If the 
criterion for a follow-up colonoscopy is changed to any adenomatous polyp regardless of size 
or histology, the cost per life-year gained is $ 2,486. Sonnenberg et al (2000) find that the cost 
per life-year gained is $ 74,032 for a combination of annual FOBT and flexible 
sigmoidoscopy every fifth year. All of these studies include direct program costs and 
consequences, but not indirect program costs and consequences.  
 We know from RCT that FOBT significantly reduces cancer mortality (Mandel et al., 
1993, Hardcastle et al., 1996, Kronborg et al., 1996 and 2004). The reduction is between 16 
and 20 percent. Gyrd-Hansen et al. (1998) find that the cost per life-year gained is Euro    29 
2,277
21 when screening individuals 65 to 74 years every second year. This estimate does not 
include treatment costs, which would be expected to reduce the cost per life-year gained. 
Whynes et al. (1998) finds that the cost per QALY gained is between Euro 2,164 and Euro 
8,977 depending on time horizon in the analysis and the costs included
22.  
In this study, cost-effectiveness analysis is applied to estimate costs per life-year 
gained. Estimating the health effect in life-years gained implies that every year the individual 
is not dead counts equally. It is a simple measure to capture, but it only includes the effect of 
screening on mortality and not the gain from screening on morbidity. Drummond et al. (2005) 
present some situations where it is preferable to use quality adjusted life-years (QALY). For 
example, when the expected health effects include both mortality and morbidity, and when it 
is relevant to make comparisons with other programs using QALYs as a health measure. A 
QALY represents a measure for which improvement in quality of life and not perfect health is 
the main outcome. In this study, the model counts a year not dead as one year, while if we had 
included QALYs in the analysis, a year under treatment would not be counted as one year. 
Introducing QALYs as the health measure will have an uncertain effect on the cost-
effectiveness because it will affect the health outcome in several ways: first, participation in 
screening will imply a reduction in quality of life, as participation could heighten anxiety. 
Second, during treatment for colorectal cancer the quality of life will be reduced. An 
asymptomatic cancer is less severe; hence, quality of life should be expected to be higher for 
individuals diagnosed with asymptomatic cancer than with a symptomatic cancer. Finally, 
screening with flexible sigmoidoscopy and colonoscopy is expected to reduce the prevalence 
of colorectal cancer. The first effect will increase the cost per QALY, the second and third 
effects will reduce the cost per QALY. The total effect is therefore uncertain. We know from 
a cost-effectiveness analysis of a follow-up program of colorectal treatment, that the QALY 
of Dukes B and Dukes C are measured to 0.83, see Norum and Olsen (1997). As QALYs are 
often used in economic evaluations, using life-years gained makes it difficult to compare 
different strategies or different health programs; thus, further research should also include an 
estimate with QALYs. 
  Two types of biases can occur in an evaluation of cost per life-year gained of a 
screening program: length bias and lead-time bias. Length bias occurs because screen-
detected cancers are prone to be less aggressive cancers. An aggressive cancer has a short 
asymptomatic period, defined as the period in which the cancer can be diagnosed with a 
                                                 
21 The costs are in 1993 DKK and Euro 1 = DKK 7.466 
22 The costs are in £ 1995-96 and Euro 1 = £ 0.633    30 
screening test. Therefore, most aggressive cancers are diagnosed due to symptoms. The less 
aggressive cancers are over-represented in the screening cohort because they have a longer 
asymptomatic period and are more likely to be present (detectable) at any particular point in 
time (time of the screening examination). As the probability of cure and survival is higher for 
a patient with less aggressive cancer than for patients with more aggressive cancers, screening 
may not have an effect on survival. Lead-time bias occurs when screening falsely prolongs 
survival. Through screening, the cancer is diagnosed earlier than when diagnosed due to 
symptoms, but the outcome in terms of date of death remains unchanged by screening 
intervention. Thus, the individual will gain no additional life-years. The time for diagnosis has 
only been moved forward. The patient's awareness of having cancer and level of anxiety will 
be extended causing a reduction in quality of life.  
  Lead time bias can only influence the findings in this model because of potential bias 
in the estimation of the transition from treatment of asymptomatic diagnosed colorectal cancer 
to death. In the estimation of survival we normalise all the dates of diagnosis to zero, i.e. 
survival is measured as the time alive from the time of diagnosis. Thus we can not be sure 
whether increased survival is due to earlier diagnosis or true prolonged survival. To adjust for 
this potential bias, we have run the model with the assumption that the transition from 
treatment of asymptomatic diagnosed colorectal cancer to death is the same as for 
symptomatic diagnosed cancers. Life-years gained changes by definition for all age groups, 
but with two decimals the change can only be seen in the age group 50 to 54 years with a 
reduction of 0.01 for both screening groups. This indicates that lead time bias is not a serious 
problem in this cost-effectiveness analysis.   
  A multinomial logit is used to estimate the transition from well to colorectal cancer or 
death. If observations for the same individual are not independent over periods, the estimated 
transition will be biased. For example, if the probability of staying well depends on individual 
characteristics the observations will not be independent. We tried to estimate a model that 
took into account that the observations may not be independent, but are not included because 
finding proper starting values in the maximum likelihood estimations was problematic. Future 
research should focus on this problem in order to further improve the modelling.     
  Whether false positives are a problem in this analysis depends on the definition of 
false positive. If false positive is defined as undergoing treatment of colorectal cancer without 
having colorectal cancer, there are no false positives. But, if false positive is defined as the 
proportion of the individuals referred to a work-up colonoscopy that never would have 
developed colorectal cancer, false positives do exist in this analysis. In the NORCCAP study    31 
the criteria for a work-up colonoscopy was a positive flexible sigmoidoscopy and/or a 
positive FOBT. A positive sigmoidoscopy is defined as having an adenoma ≤ 10 mm and/or 
having a polyp ≥ 10 mm (it is more than 95 percent certain that such a polyp is an adenoma). 
As only a proportion of these adenomas and polyps develop into cancer in the future, many 
are examined with colonoscopy without any personal benefit. How to define the inclusion 
criteria for a work-up colonoscopy requires that the proportion of false positives is balanced 
with the proportion of false negatives. If the number of individuals referred to work-up 
colonoscopy is reduced the number of false positives will decline, while the number of false 
negatives will increase.        
  As a consequence of reducing the incidence of colorectal cancer and postponing 
deaths, individuals will, on average, live longer. There are several changes in resource 
allocation that are not included in the analyses, such as increased use and need of: nursing 
homes, home nursing care and help services, terminal care, and visits to a general practitioner. 
There has been a discussion in the literature about whether or not these costs should be 
included in the cost-effectiveness analysis, see Garber and Phelps (1997), Meltzer (1997), 
Weinstein et al. (1997) and Johannesson and Meltzer (1998). Obtaining estimates of these 
costs is difficult because of the lack of available data. Including these future costs will 
increase the cost per life-year gained in all health care interventions, thus inclusion of future 
costs in screening for colorectal cancer will not necessarily entail that screening becomes less 
preferable compared with other interventions. On the other hand, these future costs will have 
a greater impact on the cost per life-year gained for the age group 60 to 64 than for the age 
group 55 to 59 years and 50 to 54 years due to discounting. Future costs in the last years of 
life will, for instance, be discounted for 10 more years in the age group 50 to 54 years than in 
the age group 60 to 64 and thus weigh relatively less in the cost per life-years gained.  
  
 
9. Concluding remarks 
  The results of this study indicate that screening for colorectal cancer by means of 
FOBT combined with flexible sigmoidoscopy is cost-effective for the age groups 55 to 59 
years and 60 to 64 years depending on which screening costs are included in the model. When 
the screening costs include direct program costs, screening the age group 55 to 59 years is the 
most cost-effective, while when indirect direct program costs are included screening the age 
group 60 to 64 years with a combination of flexible sigmoidoscopy and FOBT is most cost-   32 
effective. Inclusion of treatment costs implies that screening with a combination of flexible 
sigmoidoscopy and FOBT in the age group 55 to 59 years is most cost-effective.   
  As the differences in the transition probabilities and costs are non-significant, the cost-
effectiveness analyses are not robust. If the robustness improves with the availability of 
additional data, the insurer would have a stronger argument for introducing screening to the 
age group 55 to 59 years in the general population. In the model any differences between the 
screening groups and the control group with regard to the probability of developing colorectal 
cancer are only included for the six first cycles. Thus the effect of screening on future 
probability of developing colorectal cancer is not included. Additional data will continually 
update this transition from well to colorectal cancer and any effect of screening on the 
probability of developing cancer will gradually be included.   
      To improve our understanding of the consequences of once-only screening for 
colorectal cancer with flexible sigmoidoscopy and FOBT, there should be more research on 
the dynamics in the transitions between different states. Access to more data can give us the 
information needed. Further, there is much information to be obtained from the different 
subsamples, e.g. participants, non-participants, and those excluded. If the probability of 
developing cancer among non-participants is higher than in the control group, the insurer has 
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Appendix: 
A1. The sample 
 
 
 Total Sample  
   100,588 
 Control 
  79,808 
Intervention group 
         20,780 
Not included 
       617 
Included 
  79,191 
Participants 
    12,960 
Non-participants and others 




   12,874 
Included 
   7,685 
Not included 
       176  
 
Figure A1: Number of individuals in the study according to participation status and groups 




Intervention (half of the cohort): 1935, 1936, 1938, 1940, 1942, 1944    
Control (half of the cohort): 1935, 1936, 1938, 1940, 1942, 1944 
2000: 
Intervention (half of the cohort): 1937, 1939, 1941, 1943, 1945    
Control (half of the cohort): 1937, 1939, 1941, 1943, 1945    37 
2001: 
Intervention (half of the cohort): 1946, 1947, 1948, 1949, 1950    




Intervention (1/6 of the cohort): 1935, 1936, 1938, 1940, 1942, 1944    
Control (5/6 of the cohort): 1935, 1936, 1938, 1940, 1942, 1944 
2000: 
Intervention (1/6 of the cohort): 1937, 1939, 1941, 1943, 1945    
Control (5/6 of the cohort): 1937, 1939, 1941, 1943, 1945 
2001: 
Intervention (1/6 of the cohort): 1946, 1947, 1948, 1949, 1950    
Control (5/6 of the cohort): 1946, 1947, 1948, 1949, 1950 
 
Further assumptions: 
CRC and deaths are included from the year the individuals either were invited to screening or 
were assumed to be part of the control group. For the age cohorts 1935, 1936, 1938, 1940, 
1942 and 1944 we include all cancers and deaths from 01.01.99 for both intervention and 
control group; for the age cohorts 1937, 1939, 1941, 1943 and 1945, we include cancers and 
deaths from 01.01.00 for both intervention and control group; and for the age cohorts 1946, 
1947, 1948, 1949 and 1950, we include cancers and deaths from 01.01.01 for both 
intervention and control group. 
 
A2. Fractions applied in the model   
Table A1: Fractions applied in the model according to screening strategy and age group
23. 
Probability FS5054  COMB5054 FS5559 COMB5559 FS6064 COMB6064
a   0.59 0.57 0.66 0.62 0.66 0.63 
h   0.09 0.08 0.12 0.11 0.13 0.12 
c  0.00162  0.0013 0.00246  0.0202 0.00237  0.00263 
m   0  0.51 0  0.51 0  0.51 
 
 
                                                 
23 FS refers to flexible sigmoidoscopy and COMB refers to the combination of flexible sigmoidoscopy and 
FOBT    38 
A3. Descriptive statistics 
Table A2: The estimated transition from well to death from causes other than colorectal 
cancer  applied in the model according screening strategy, age group and stage. 
Stage  50 to 54 years  55 to 59 years  60 to 64 years 
  C  FS COMB  C  FS COMB  C  FS COMB 
0  0.00205 0.00207 0.00180  0.0047 0.0044 0.0039 0.0072 0.0070 0.0063 
1  0.00222 0.00224 0.00195  0.0051 0.0047 0.0042 0.0078 0.0075 0.0068 
2  0.00241 0.00242 0.00211  0.0055 0.0051 0.0046 0.0084 0.0082 0.0073 
3  0.00260 0.00262 0.00228  0.0060 0.0055 0.0050 0.0091 0.0088 0.0079 
4  0.00282 0.00284 0.00247  0.0065 0.0060 0.0054 0.0099 0.0096 0.0086 
5  0.00305 0.00307 0.00267  0.0070 0.0065 0.0058 0.0107 0.0103 0.0093 
6  0.00576 0.00576 0.00576  0.0079 0.0079 0.0079 0.0136 0.0136 0.0136 
7  0.00585 0.00585 0.00585  0.0101 0.0101 0.0101 0.0157 0.0157 0.0157 
8  0.00706 0.00706 0.00706  0.0105 0.0105 0.0105 0.0172 0.0172 0.0172 
9  0.00697 0.00697 0.00697  0.0122 0.0122 0.0122 0.0192 0.0192 0.0192 
10  0.00706 0.00706 0.00706  0.0128 0.0128 0.0128 0.0212 0.0212 0.0212 
11  0.00793 0.00793 0.00793  0.0136 0.0136 0.0136 0.0230 0.0230 0.0230 
12  0.01007 0.01007 0.01007  0.0157 0.0157 0.0157 0.0261 0.0261 0.0261 
13  0.01045 0.01045 0.01045  0.0172 0.0172 0.0172 0.0285 0.0285 0.0285 
14  0.01220 0.01220 0.01220  0.0192 0.0192 0.0192 0.0330 0.0330 0.0330 
15  0.01282 0.01282 0.01282  0.0212 0.0212 0.0212 0.0365 0.0365 0.0365 
16  0.01356 0.01356 0.01356  0.0230 0.0230 0.0230 0.0394 0.0394 0.0394 
17  0.01574 0.01574 0.01574  0.0261 0.0261 0.0261 0.0453 0.0453 0.0453 
18  0.01716 0.01668 0.01668  0.0285 0.0285 0.0285 0.0555 0.0555 0.0555 
19  0.01924 0.01876 0.01876  0.0330 0.0330 0.0330 0.0622 0.0622 0.0622 
20  0.02119 0.02119 0.02119  0.0365 0.0365 0.0365 0.0679 0.0679 0.0679 
21  0.02298 0.02298 0.02298  0.0394 0.0394 0.0394 0.0722 0.0722 0.0722 
22  0.02611 0.02611 0.02611  0.0453 0.0453 0.0453 0.0863 0.0863 0.0863 
23  0.02855 0.02779 0.02779  0.0555 0.0555 0.0555 0.0917 0.0917 0.0917 
24  0.03299 0.03223 0.03223  0.0622 0.0622 0.0622 0.1033 0.1033 0.1033 
25  0.03648 0.03648 0.03648  0.0679 0.0679 0.0679 0.1144 0.1144 0.1144 
26  0.03942 0.03942 0.03942  0.0722 0.0722 0.0722 0.1342 0.1342 0.1342 
27  0.04528 0.04528 0.04528  0.0863 0.0863 0.0863 0.1487 0.1487 0.1487 
28  0.05547 0.05499 0.05499  0.0917 0.0917 0.0917 0.1609 0.1609 0.1609 
29  0.06218 0.06170 0.06170  0.1033 0.1033 0.1033 0.1795 0.1795 0.1795 
30  0.06791 0.06791 0.06791  0.1144 0.1144 0.1144 0.2031 0.2031 0.1605 
31  0.07217 0.07217 0.07217  0.1342 0.1342 0.1342 0.2122 0.2122 0.1791 
32  0.08630 0.08630 0.08630  0.1487 0.1487 0.1487 0.2404 0.2404 0.2031 
33  0.09169 0.09001 0.09001  0.1609 0.1609 0.1609 0.2504 0.2504 0.2122 
34  0.10335 0.10167 0.10167  0.1795 0.1795 0.1795 0.2854 0.2854 0.2404 
35  0.11441 0.11441 0.11441  0.2031 0.2031 0.2031 0.3204 0.3204 0.2504 
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Table A3: The estimated transition from well to colorectal cancer applied in the model 
according to screening strategy, age group and stage. 
Stage  50 to 54 years  55 to 59 years  60 to 64 years 
 C  FS  COMB  C  FS  COMB  C FS  COMB 
0  0.00027 0.00028 0.00027 0.00071 0.00039 0.00047  0.00125 0.00119 0.00105 
1  0.00029 0.00030 0.00029 0.00075 0.00042 0.00050  0.00133 0.00128 0.00112 
2  0.00031 0.00032 0.00031 0.00081 0.00044 0.00054  0.00142 0.00136 0.00120 
3  0.00033 0.00034 0.00033 0.00086 0.00047 0.00057  0.00152 0.00146 0.00128 
4  0.00035 0.00036 0.00035 0.00092 0.00051 0.00061  0.00162 0.00156 0.00137 
5  0.00037 0.00039 0.00038 0.00098 0.00054 0.00065  0.00173 0.00166 0.00146 
6  0.00089 0.00089 0.00089 0.00140 0.00140 0.00126  0.00227 0.00227 0.00227 
7  0.00140 0.00140 0.00140 0.00227 0.00227 0.00204  0.00313 0.00313 0.00313 
8  0.00140 0.00140 0.00140 0.00227 0.00227 0.00204  0.00313 0.00313 0.00313 
9  0.00140 0.00140 0.00140 0.00227 0.00227 0.00204  0.00313 0.00313 0.00313 
10  0.00140 0.00140 0.00140 0.00227 0.00227 0.00204  0.00313 0.00313 0.00313 
11  0.00140 0.00140 0.00140 0.00227 0.00227 0.00204  0.00313 0.00313 0.00313 
12  0.00227 0.00227 0.00227 0.00313 0.00313 0.00282  0.00413 0.00413 0.00413 
13  0.00227 0.00227 0.00227 0.00313 0.00313 0.00282  0.00413 0.00413 0.00413 
14  0.00227 0.00227 0.00227 0.00313 0.00313 0.00282  0.00413 0.00413 0.00413 
15  0.00227 0.00227 0.00227 0.00313 0.00313 0.00282  0.00413 0.00413 0.00413 
16  0.00227 0.00227 0.00227 0.00313 0.00313 0.00282  0.00413 0.00413 0.00413 
17  0.00313 0.00313 0.00313 0.00413 0.00413 0.00372  0.00476 0.00476 0.00476 
18  0.00313 0.00313 0.00313 0.00413 0.00413 0.00372  0.00476 0.00476 0.00476 
19  0.00313 0.00313 0.00313 0.00413 0.00413 0.00372  0.00476 0.00476 0.00476 
20  0.00313 0.00313 0.00313 0.00413 0.00413 0.00372  0.00476 0.00476 0.00476 
21  0.00313 0.00313 0.00313 0.00413 0.00413 0.00372  0.00476 0.00476 0.00476 
22  0.00413 0.00413 0.00413 0.00476 0.00476 0.00428  0.00464 0.00464 0.00464 
23  0.00413 0.00413 0.00413 0.00476 0.00476 0.00428  0.00464 0.00464 0.00464 
24  0.00413 0.00413 0.00413 0.00476 0.00476 0.00428  0.00464 0.00464 0.00464 
25  0.00413 0.00413 0.00413 0.00476 0.00476 0.00428  0.00464 0.00464 0.00464 
26  0.00413 0.00413 0.00413 0.00476 0.00476 0.00428  0.00464 0.00464 0.00464 
27  0.00476 0.00476 0.00476 0.00464 0.00464 0.00418  0.00464 0.00464 0.00464 
28  0.00476 0.00476 0.00476 0.00464 0.00464 0.00418  0.00464 0.00464 0.00464 
29  0.00476 0.00476 0.00476 0.00464 0.00464 0.00418  0.00464 0.00464 0.00464 
30  0.00476 0.00476 0.00476 0.00464 0.00464 0.00418  0.00464 0.00464 0.00464 
31  0.00476 0.00476 0.00476 0.00464 0.00464 0.00418  0.00464 0.00464 0.00464 
32  0.00464 0.00464 0.00464 0.00464 0.00464 0.00418  0.00464 0.00464 0.00464 
33  0.00464 0.00464 0.00464 0.00464 0.00464 0.00418  0.00464 0.00464 0.00464 
34  0.00464 0.00464 0.00464 0.00464 0.00464 0.00418  0.00464 0.00464 0.00464 
35  0.00464 0.00464 0.00464 0.00464 0.00464 0.00418  0.00464 0.00464 0.00464 
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Table A4: The estimated transition from colorectal cancer to death for symptomatic 
diagnosed cancers applied in the model according to time from diagnosis, age group and 
stage. 
Stage  Symptomatic diagnosed cancers 
  Year 1  Year 2  Year 3  Year 4 
  5054 5559 6064 5054 5559 6064 5054 5559 6064 5054 5559 6064 
0  0.123 0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123 
1  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123 
2  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123 
3  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123 
4  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123 
5  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123  0.123 
6  0.227 0.227 0.227 0.078 0.078 0.078 0.051 0.051 0.051 0.035 0.035 0.035 
7  0.227 0.227 0.227 0.078 0.078 0.078 0.051 0.051 0.051 0.035 0.035 0.035 
8  0.227 0.227 0.199 0.078 0.078 0.069 0.051 0.051 0.045 0.035 0.035 0.031 
9  0.227 0.227 0.199 0.078 0.078 0.069 0.051 0.051 0.045 0.035 0.035 0.031 
10  0.227 0.227 0.199 0.078 0.078 0.069 0.051 0.051 0.045 0.035 0.035 0.031 
11  0.227 0.227 0.209 0.078 0.078 0.072 0.051 0.051 0.047 0.035 0.035 0.032 
12  0.227 0.227 0.209 0.078 0.078 0.072 0.051 0.051 0.047 0.035 0.035 0.032 
13  0.227 0.199 0.347 0.078 0.069 0.120 0.051 0.045 0.078 0.035 0.031 0.054 
14  0.227 0.199 0.347 0.078 0.069 0.120 0.051 0.045 0.078 0.035 0.031 0.054 
15  0.227 0.199  0.35 0.078 0.069 0.121 0.051 0.045 0.078 0.035 0.031 0.054 
16  0.227 0.209  0.35 0.078 0.072 0.121 0.051 0.047 0.078 0.035 0.032 0.054 
17  0.227 0.209 0.345 0.078 0.072 0.119 0.051 0.047 0.077 0.035 0.032 0.054 
18  0.199 0.347 0.345 0.069 0.120 0.119 0.045 0.078 0.077 0.031 0.054 0.054 
19  0.199 0.347 0.345 0.069 0.120 0.119 0.045 0.078 0.077 0.031 0.054 0.054 
20  0.199 0.35  0.345  0.069  0.121 0.119 0.045 0.078 0.077 0.031 0.054 0.054 
21  0.209 0.35  0.345  0.072  0.121 0.119 0.047 0.078 0.077 0.032 0.054 0.054 
22  0.209 0.345 0.343 0.072 0.119 0.118 0.047 0.077 0.077 0.032 0.054 0.053 
23  0.347 0.345  0.36 0.120 0.119 0.124 0.078 0.077 0.081 0.054 0.054 0.056 
24  0.347 0.345 0.373 0.120 0.119 0.129 0.078 0.077 0.084 0.054 0.054 0.058 
25  0.35 0.345 0.373 0.121 0.119 0.129 0.078 0.077 0.084 0.054 0.054 0.058 
26  0.35 0.345 0.373 0.121 0.119 0.129 0.078 0.077 0.084 0.054 0.054 0.058 
27  0.345 0.343 0.373 0.119 0.118 0.129 0.077 0.077 0.084 0.054 0.053 0.058 
28  0.345 0.36  0.373  0.119  0.124 0.129 0.077 0.081 0.084 0.054 0.056 0.058 
29  0.345 0.373 0.373 0.119 0.129 0.129 0.077 0.084 0.084 0.054 0.058 0.058 
30  0.345 0.373 0.352 0.119 0.129 0.121 0.077 0.084 0.079 0.054 0.058 0.055 
31  0.345 0.373 0.352 0.119 0.129 0.121 0.077 0.084 0.079 0.054 0.058 0.055 
32  0.343 0.373 0.352 0.118 0.129 0.121 0.077 0.084 0.079 0.053 0.058 0.055 
33  0.36 0.373 0.352 0.124 0.129 0.121 0.081 0.084 0.079 0.056 0.058 0.055 
34  0.373 0.373 0.352 0.129 0.129 0.121 0.084 0.084 0.079 0.058 0.058 0.055 
35  0.373 0.352 0.352 0.129 0.121 0.121 0.084 0.079 0.079 0.058 0.055 0.055 
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A4. Follow-up colonoscopy 
Table A5: Proportion of follow-up colonoscopy applied in the model according to screening 
strategy, age group and stage. 
Stage  50 to 54 years  55 to 59 years  60 to 64 years 
 FS  COMB  FS  COMB  FS  COMB 
0  0  0.0003  0.0002 0.0003 0.0004 0.0004 
1  0.0005 0.0022 0.003 0.003 0.0028  0.0034 
2  0.0027  0.0011  0.002  0.0018 0.0008 0.0008 
3  0.0043  0.0052  0.0205 0.0154 0.0261 0.0226 
4  0.0049  0.0036  0.0306 0.0288 0.0352 0.0283 
5  0.0281  0.0263  0.0064 0.0048 0.0028 0.0023 
6  0  0.0011  0.001  0 0 0 
7  0.0011 0  0.0007  0  0.0004  0.0008 
8  0.0019  0.0005  0.0042 0.0035 0.0036 0.006 
9  0.0019  0.0016  0.0057 0.0053 0.0032 0.0034 
10  0.0005 0.0027 0.0005  0.001 0  0.0004 
11  0 0 0  0.005  0  0 




A5. Assumptions in the sensitivity analysis 
Based on Figure A1 to A8, we assume that treatment costs are gamma distributed with α and 
λ can be estimated from the following two definitions: 
Mean = α/λ 
Variance = α/λ²  
 
Table A6: Assumptions in the probabilistic sensitivity analysis ranking the four years of 
treatment. Mean and variance are reported in NOK.  
Year Mean  St.dev.  α  λ 
Symptomatic 
                 1 
                 2 
                 3 
                 4 
 
18,880 
  4,718 
  2,734 
  1,908 
 
  785 
  735 




  41.05 
  14.49 







                 1 
                 2 
                 3 
                 4 
 
16,416 
  2,058 
    493 
    196 
 
1,610 
   765 
   194 
    82 
 
103.00 
   7.27 
   6.46 
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Figure A1: Treatment cost for asymptomatic diagnosed cancers during the first year  
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Figure A2: Treatment cost for asymptomatic diagnosed cancers during the second year  
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Figure A3: Treatment cost for asymptomatic diagnosed cancers during the third year  
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Figure A4: Treatment cost for asymptomatic diagnosed cancers during the fourth year  
after time of diagnosis. Numbers in NOK. 
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Figure A5: Treatment cost for symptomatic diagnosed cancers during the first year  
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Figure A6: Treatment cost for symptomatic diagnosed cancers during the second year  
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Figure A7: Treatment cost for symptomatic diagnosed cancers during the third year  
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Figure A8: Treatment cost for symptomatic diagnosed cancers during the fourth year  
after time of diagnosis. Numbers in NOK. 
 
 
 
 
 
 
 